Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regulus Therapeutics

1.48
+0.10007.25%
Post-market: 1.480.00000.00%17:13 EDT
Volume:245.39K
Turnover:367.02K
Market Cap:96.94M
PE:-1.60
High:1.56
Open:1.37
Low:1.35
Close:1.38
Loading ...

Company Profile

Company Name:
Regulus Therapeutics
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
32
Office Location:
4224 Campus Point Court,Suite 210,San Diego,California,United States
Zip Code:
92121
Fax:
- -
Introduction:
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Directors

Name
Position
Joseph P. Hagan
Director, President and Chief Executive Officer
Stelios Papadopoulos
Chairman of the Board
Alice S. Huang
Director
David Baltimore
Director
Hugh Rosen
Director
Jake R. Nunn
Director
Kathryn J. Collier
Director
Pascale Witz
Director
Simos Simeonidis
Director
William H. Rastetter
Director

Shareholders

Name
Position
Joseph P. Hagan
Director, President and Chief Executive Officer
Christopher Aker
Senior Vice President and General Counsel
Cris Calsada
Chief Financial Officer
Denis Drygin
Chief Scientific Officer